Moderna
MRNA
#1253
Rank
$14.31 B
Marketcap
$37.20
Share price
-6.46%
Change (1 day)
-49.80%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

P/E ratio for Moderna (MRNA)

P/E ratio as of November 2024 (TTM): -4.04

According to Moderna 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.04486. At the end of 2022 the company had a P/E ratio of 8.50.

P/E ratio history for Moderna from 2018 to 2023

PE ratio at the end of each year

Year P/E ratio Change
20228.501.4%
20218.39-115.58%
2020-53.9326.73%
2019-12.6-6.53%
2018-13.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.8462-79.08%๐Ÿ‡บ๐Ÿ‡ธ USA
53.6-1,425.11%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0045-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-59.2 1,363.53%๐Ÿ‡บ๐Ÿ‡ธ USA
27.6-781.20%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
-11.2 175.95%๐Ÿ‡บ๐Ÿ‡ธ USA
10.9-370.67%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.